Critical Care Market to 2019 - Growth from Factor Concentrates New Indications and Increasing Demand for Albumin in Asia-Pacific



Summary



GBI Research, the leading business intelligence provider, has released its latest research, “Critical Care Market to 2019 - Growth from Factor Concentrates New Indications and Increasing Demand for Albumin in Asia-Pacific”. The report provides in-depth analysis of the drivers and barriers that affect the global critical care market. The report has been compiled using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts.

The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries of Europe (the UK, Germany, France, Italy and Spain), and Japan. The report does also provide an overview on Asia-Pacific countries, including China, India and Australia.
The report provides an overview of major marketed products in critical care market along with treatment usage patterns, average annual cost of therapy and market forecast to 2019 for key geographical markets, as well as for leading therapeutic segments. The report also provides information on the Research and Development (R&D) product pipeline and explores the competitive landscape, including the provision of profiles for major players in the critical care market. Finally, the report includes analysis of Mergers and Acquisitions (M&A) activity in the critical care market.

GBI Research’s analysis indicates that the global critical care market is still an untapped market, with a small number of players accounting for a major proportion of the overall market. The market grew at a very slow growth rate between 2006 and 2012, possibly due to the lac of availability of many of the products in certain markets, especially in the US.
GBI Research estimates that the overall critical care therapeutics market was worth $2.3 billion in 2012, having grown in size at a CAGR of 11% from $1.2 billion in 2006. The market is expected to grow at a CAGR of 5% to reach $3.2 billion in 2019. The double-digit market growth registered between 2006 and 2012 can be attributed primarily to the increased demand for and cost of albumin, as well as the approval and launch of new products.

The growth of the overall critical care market during the forecast period is expected to be largely due to an increasing preference in the market for factor concentrates such as Riastap, Corifact, rFXIII (which has been launched in the EU and is expected to be launched in the US later this year), the expanded indication for Antithrombin (AT) III and factor concentrates, and rising demand for albumin from countries in the Asia-Pacific region. Stagnant innovations, a low prevalence rate and the consequent limited availability of patients are some of the factors impeding the growth of the critical care market.



Scope


- Data and analysis regarding the critical care market in leading geographical locations – the US, the UK, Germany, France, Italy, Spain, and Japan and Asia-Pacific countries, including India, China and Australia.
- Annualized market data for the critical care market, including the individual markets for factor XIII concentrate, fibrinogen concentrate, antithrombin, prothrombin complex concentrate and albumin from 2006 to 2012, with forecasts provided up to 2019.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, cost of therapy, sales volume, and treatment usage patterns, such as disease population, diagnosis population and prescription population.
- Key drivers and restraints that have had a major impact upon the market.
- An overview of the competitive landscape of the global critical care market, including benchmarking for leading companies. Some of the key companies studied in this report are CSL, Octapharma, Baxter, Grifols, and LFB.
- Key M&A activities that took place in 2010 and 2011 in the critical care market.



Reasons to buy


- Align company product portfolios to markets with high growth potential.
- Build effective strategies to launch pipeline products, by identifying potential geographical markets.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms capable of producing first-in-class molecules which are safer and more efficacious

Table Of Contents

Table of Contents

1 Table of CContents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
3 Critical Care Market to 2019 - Global Overview 11
4 Critical Care Market to 2019 - Geographical Landscape 13
4.1 Introduction 13
4.2 The US - Critical Care Market 14
4.2.1 Revenue 14
4.3 Top Five European Countries - Critical Care Market 16
4.3.1 Revenue 16
4.4 Japan - Critical Care Market 18
4.4.1 Revenue 18
5 Critical Care Market to 2019 - Albumin Market 19
5.1 Introduction 19
5.2 Marketed Albumin Products 21
5.2.1 Buminate 21
5.2.2 Zenalb 21
5.2.3 Human Albumin Biotest 21
5.2.4 AlbuRx 22
5.2.5 Albuminar 22
5.2.6 Albutein 22
5.2.7 Albuked 23
5.2.8 Vialebex 23
5.2.9 Albunorm 23
5.2.10 AlbuRAAS 23
5.3 Revenue 24
5.4 Cost of Therapy 26
5.5 China 27
5.5.1 Introduction 27
5.5.2 Strict Regulatory Reforms Leading to Tighter Supply 27
5.5.3 Fragmented Market Dominated by Overseas Players 27
5.5.4 Price of Albumin Likely to Remain High 27
5.5.5 Conclusion 28
5.6 India 28
5.7 Australia 28
5.7.1 Introduction 28
5.7.2 Rising Albumin Demand 29
5.7.3 Australian Albumin Market 29
5.8 Market Drivers and Barriers 30
5.8.1 Market Drivers 30
5.8.2 Market Barriers 31
6 Critical Care Market to 2019 - Antithrombin Concentrate Market 32
6.1 Introduction 32
6.1.1 Marketed Antithrombin Concentrate Products 33
6.1.2 Revenue 38
6.1.3 Geographical Segmentation 40
6.1.4 Cost of Treatment 42
6.1.5 Treatment Usage Pattern 43
6.2 Drivers and Restraints 45
6.2.1 Drivers 45
6.2.2 Restraints 46
7 Critical Care Market to 2019 - Fibrinogen Concentrate Market 47
7.1 Introduction 47
7.2 Marketed Fibrinogen Concentrates 48
7.2.1 Haemocomplettan/Riastap 48
7.2.2 Clottafact 48
7.2.3 Other Marketed Fibrinogen Concentrates 49
7.2.4 Revenue 49
7.2.5 Geographical Segmentation 51
7.3 Market Segmentation 53
7.3.1 Cost of Treatment 55
7.4 Treatment Usage Pattern 56
7.5 Drivers and Barriers 59
7.5.1 Drivers 59
7.5.2 Barriers 60
8 Critical Care Market to 2019 - Prothrombin Complex Concentrate Market 61
8.1 Introduction 61
8.2 Marketed Products 63
8.2.1 Beriplex P/N 63
8.2.2 Confidex 63
8.2.3 Profilnine SD 63
8.2.4 Uman Complex DI 64
8.2.5 Kaskadil 64
8.2.6 Octaplex 500 64
8.2.7 Cofact 64
8.2.8 Feiba VH 64
8.2.9 Bebulin VH 65
8.3 Revenue 65
8.3.1 Revenue Breakdown 67
8.4 Geographical Segmentation 68
8.5 Cost of Therapy 69
8.5.1 Treatment Usage Pattern 71
8.6 Drivers and Restraints 72
8.6.1 Drivers 72
8.6.2 Barriers 73
9 Critical Care Market to 2019 - Factor XIII Concentrate Market 74
9.1 Introduction 74
9.2 Marketed Products 75
9.2.1 Fibrogammin / Corifact 75
9.3 Revenue 76
9.3.1 Geographical Segmentation 78
9.3.2 Cost of Treatment 81
9.3.3 Treatment Usage Pattern 83
9.4 Drivers and Restraints 85
9.4.1 Drivers 85
9.4.2 Restraint 86
10 Critical Care Market to 2019 - Research and Development Product Pipeline 87
10.1 Introduction 87
10.1.1 rFXIII (NovoThirteen) 89
11 Critical Care Market to 2019 - Competitive Landscape 90
11.1 CSL Limited 90
11.2 Baxter International Incorporated 90
11.3 Grifols, SA 90
11.4 Octapharma AG 90
11.5 Kedrion SpA 91
11.6 Biotest 91
11.7 Laboratoire Français de Fractionnement et de Biotechnologies 91
11.8 Bio Products Laboratory Limited 91
11.9 Sanquin Blood Supply Foundation 91
11.10 China Biologic Products, Incorporated 92
11.11 Hualan Biological Engineering, Incorporated 92
11.12 Shanghai RAAS Blood Products Company, Limited 92
12 Critical Care Market to 2019 - Strategic Consolidation 93
12.1 Grifols Acquisition of Talecris Biotherapeutics in June 2011 93
12.2 LFB Biotechnologies Acquisition of GTC Biotherapeutics in December 2010 93
12.3 ViroPharma Expands Licensing Agreement with Sanquin Blood Supply Foundation in January 2010 94
13 Critical Care Market to 2019 - Appendix 95
13.1 Market Definitions 95
13.2 Abbreviations 95
13.3 Bibliography 96
13.4 Research Methodology 98
13.4.1 Coverage 98
13.4.2 Secondary Research 98
13.4.3 Primary Research 99
13.5 Therapeutic Landscape 99
13.5.1 Market 101
13.6 Geographical Landscape 102
13.7 Pipeline Analysis 102
13.8 Competitive Landscape 102
13.8.1 Expert Panel Validation 102
13.9 Contact Us 102
13.10 Disclaimer 102



List of Tables

Table 1: Critical Care Market, Global, Revenue ($bn), 2006-2012 12
Table 2: Critical Care Market, Global, Revenue Forecast ($bn), 2012-2019 12
Table 3: Critical Care Market, US, Revenue ($m), 2006-2012 15
Table 4: Critical Care Market, US, Revenue Forecast ($m), 2012-2019 15
Table 5: Critical Care Market, Top Five European Countries, Revenue ($m), 2006-2012 17
Table 6: Critical Care Market, Top Five European Countries, Revenue Forecast ($m), 2012-2019 17
Table 7: Critical Care Market, Japan, Revenue ($m), 2006-2012 18
Table 8: Critical Care Market, Japan, Revenue Forecast ($m), 2012-2019 18
Table 9: Critical Care Market, Global, Albumin, Revenue ($m), 2006-2012 24
Table 10: Critical Care Market, Global, Albumin, Revenue Forecast ($m), 2012-2019 24
Table 11: Critical Care Market, Australia, Albumin Demand (kg), 2004-2012 29
Table 12: Critical Care Market, Global, Available Antithrombin Concentrate Products, 2013 33
Table 13: Critical Care Market, Global, Antithrombin Concentrate, Revenue ($m), 2006-2012 39
Table 14: Critical Care Market, Global, Antithrombin Concentrate, Revenue Forecast ($m), 2012-2019 39
Table 15: Critical Care Market, Global, Antithrombin Concentrate, Revenue ($m), 2006-2012 40
Table 16: Critical Care Market, Global, Antithrombin Concentrate, Revenue Forecast ($m), 2012-2019 41
Table 17: Critical Care Market, Global, Antithrombin Cost of Therapy ($), 2006-2012 42
Table 18: Critical Care Market, Global, Antithrombin, Cost of Therapy Forecast ($), 2012-2019 42
Table 19: Critical Care Market, Global, Antithrombin, Treatment Usage Pattern (‘000), 2006-2012 43
Table 20: Critical Care Market, Global, Antithrombin, Treatment Usage Pattern Forecast (‘000), 2012-2019 43
Table 21: Critical Care Market, Global, Fibrinogen Concentrate, Revenue ($m), 2006-2012 50
Table 22: Critical Care Market, Global, Fibrinogen Concentrate, Revenue Forecast ($m), 2012-2019 50
Table 23: Critical Care Market, Global, Fibrinogen Concentrate, Revenue by Country ($m), 2006-2012 51
Table 24: Critical Care Market, Global, Fibrinogen Concentrate, Revenue by Country ($m), 2012-2019 52
Table 25: Critical Care Market, Global, Fibrinogen Concentrate, Cost of Therapy ($), 2006-2012 55
Table 26: Critical Care Market, Global, Fibrinogen Concentrate, Cost of Therapy Forecast ($), 2012-2019 55
Table 27: Critical Care Market, Global, Fibrinogen Concentrate, Epidemiology, 2006-2012 57
Table 28: Critical Care Market, Global, Fibrinogen Concentrate, Epidemiology, 2012-2019 57
Table 29: Critical Care Market, Global, Fibrinogen Concentrate, Diagnosed Cases, 2006-2011 58
Table 30: Critical Care Market, Global, PCC, Revenue ($m), 2006-2012 66
Table 31: Critical Care Market, Global, PCC, Revenue ($m), 2012-2019 66
Table 32: Critical Care Market, Global, PCC, Revenue Segmentation ($m), 2006-2012 68
Table 33: Critical Care Market, Global, PCC, Revenue Segmentation ($m), 2012-2019 69
Table 34: Critical Care Market, Global, PCC, Cost of Therapy ($), 2006-2012 70
Table 35: Critical Care Market, Global, PCC, Cost of Therapy ($), 2012-2019 70
Table 36: Critical Care Market, Global, PCC, Number of Patients on PCC (‘000), 2006-2012 71
Table 37: Critical Care Market, Global, PCC, Number of Patients on PCC (‘000), 2012-2019 71
Table 38: Critical Care Market, Global, Factor XIII Concentrate, Revenue ($m), 2006-2012 76
Table 39: Critical Care Market, Global, Factor XIII Concentrate, Revenue ($m), 2012-2019 76
Table 40: Critical Care Market to 2019, Global, Factor XIII Concentrate, Revenue Segmentation ($’000), 2006-2012 78
Table 41: Critical Care Market, Global, Factor XIII Concentrate, Revenue Segmentation ($’000), 2012-2019 79
Table 42: Critical Care Market, Global, Factor XIII Concentrate, Cost of Therapy ($), 2006-2012 81
Table 43: Critical Care Market, Global, Factor XIII Concentrate, Cost of Therapy ($), 2012-2019 81
Table 44: Critical Care Market, Global, Factor XIII Concentrate, Treatment Usage Pattern, 2006-2012 83
Table 45: Critical Care Market, Global, Factor XIII Concentrate, Treatment Usage Pattern, 2012-2019 83
Table 46: Critical Care Market, Global, Factor XIII Concentrate, Reported Diagnosed Cases of FXIII Deficient Patients, 2006-2011 84
Table 47: Critical Care Market, Product Pipeline by Indication, 2013 87



List of Figures

Figure 1: Critical Care Market, Global, Revenue Forecast ($bn), 2006-2019 12
Figure 2: Critical Care Market, Global, Revenue by Geography (%), 2012 13
Figure 3: Critical Care Market, US, Revenue Forecast ($m), 2006-2019 15
Figure 4: Critical Care Market, Global, Revenue ($m), 2012 16
Figure 5: Critical Care Market, Top Five European Countries, Revenue Forecast ($m), 2006-2019 17
Figure 6: Critical Care Market, Japan, Revenue Forecast ($m), 2006-2019 18
Figure 7: Critical Care Market, Global, Albumin, Revenue Forecast ($bn), 2006-2019 24
Figure 8: Critical Care Market, Global, Albumin, Average Price ($), 1998-2012 26
Figure 9: Critical Care Market, Australia, Albumin Demand (kg), 2004-2012 29
Figure 10: Critical Care Market, Global, Albumin, Drivers and Restraints, 2012 30
Figure 11: Critical Care Market, Global, Antithrombin Concentrate, Revenue Forecast ($m), 2006-2019 38
Figure 12: Critical Care Market, Global Antithrombin Market Breakup (%), 2012 39
Figure 13: Critical Care Market, Global, Antithrombin Concentrate, Revenue Forecast ($m), 2006-2019 40
Figure 14: Critical Care Market, Global, Antithrombin, Cost of Therapy Forecast ($), 2006-2019 42
Figure 15: Critical Care Market, Global, Antithrombin, Treatment Usage Pattern Forecast (‘000), 2006-2019 43
Figure 16: Critical Care Market, Global, Antithrombin, Drivers and Restraints, 2012 45
Figure 17: Critical Care Market, Global, Fibrinogen Concentrate, Revenue Forecast ($m), 2006-2019 50
Figure 18: Critical Care Market, Global, Fibrinogen Concentrate, Revenue Segmentation ($m) Forecast, 2006-2019 51
Figure 19: Critical Care Market, Global Fibrinogen Concentrate Market Breakup (%), 2012 53
Figure 20: Critical Care Market, Global, Fibrinogen Concentrate, Cost of Therapy ($), 2006-2019 55
Figure 21: Critical Care Market, Global, Fibrinogen Concentrate, Treatment Usage Pattern, 2006-2019 56
Figure 22: Critical Care Market, Global Fibrinogen Concentrate Market, Drivers and Restraints, 2012 59
Figure 23: Critical Care Market, Global, PCC, Revenue ($m), 2006-2019 66
Figure 24: Critical Care Market, Global, PCC Market Breakdown (%), 2012 67
Figure 25: Critical Care Market, Global, PCC, Revenue Segmentation ($m), 2006-2019 68
Figure 26: Critical Care Market, Global, PCC, Cost of Therapy ($), 2006-2019 69
Figure 27: Critical Care Market, Global, PCC, Number of Patients on PCC, 2006-2019 71
Figure 28: Critical Care Market, Global PCC Market, Drivers and Restraints, 2012 72
Figure 29: Critical Care Market, Global, Factor XIII Concentrate, Revenue ($m), 2006-2019 76
Figure 30: Critical Care Market, Global, Factor XIII Concentrate, Revenue Segmentation ($m), 2006-2019 78
Figure 31: Critical Care Market, Global, Factor XIII Concentrate Market Breakup (%), 2012 80
Figure 32: Critical Care Market, Global, Factor XIII Concentrate, Cost of Therapy ($), 2006-2019 81
Figure 33: Critical Care Market, Global, Factor XIII Concentrate, Treatment Usage Pattern, 2006-2019 83
Figure 34: Critical Care Market, Global, Factor XIII Concentrate Market, Drivers and Restraints, 2012 85
Figure 35: GBI Research Market Forecasting Model 101



Companies Mentioned

CSL Limited
Baxter International Incorporated
Grifols, SA
Octapharma AG
Kedrion SpA
Biotest
Laboratoire Français de Fractionnement et de Biotechnologies
Bio Products Laboratory Limited
Sanquin Blood Supply Foundation
China Biologic Products, Incorporated
Hualan Biological Engineering, Incorporated
Shanghai RAAS Blood Products Company, Limited

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

Global Organ and Tissue Transplantation Market

Global Organ and Tissue Transplantation Market

  • $ 4 950
  • Industry report
  • September 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Organ and Tissue Transplantation in Number of Procedures. The global and regional markets (except the US) for 'Organ and Tissue Transplantation' in this report ...

Global Organ Preservation Solutions Market 2014-2018

Global Organ Preservation Solutions Market 2014-2018

  • $ 2 500
  • Industry report
  • October 2014
  • by Infiniti Research Limited

About Organ Preservation Solutions Organ preservation solutions help preserve the organs for a longer period when they are outside the living body. The preservation of organ is done for various applications ...

Plasma Etching: Market Analysis and Strategic Issues

Plasma Etching: Market Analysis and Strategic Issues

  • $ 2 495
  • Industry report
  • October 2014
  • by Information Network

The future needs in plasma etching will be for ever tighter control of process variability, higher selectivity and less damage. This report addresses the strategic issues impacting both the user and supplie ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.